Please assess the completion status of the following clinical trial:

Trial Title: Lurasidone and Cognition in Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients must be taking either lithium or valproate or one of the atypical antipsychotics for mood stabilization.~2. Patients who show cognitive impairments (-0.25 standard deviations (SD) or below) on either the Trail Making Test- trial B (TMT-B) or California Verbal Learning Test (CVLT) trials 1 to 5, or CVLT long delay free recall, at baseline visit.~3. Males or females aged 19 to 65 years inclusive.~4. Diagnostic and Statistical Manual IV edition (DSM-IV TR) diagnosis of Bipolar Type I Disorder, with or without a history of psychosis.~5. Clinically stable with a Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) score less than or equal to 8.~6. A sufficient level of English using a language screening questionnaire.~7. Capability of understanding, consenting to, and complying with the requirements of the study.~Exclusion Criteria:~1. A history of unstable or inadequately treated medical illnesses, including moderate to severe brain injury, or neurological illnesses impacting cognitive function.~2. Treatment with Electroconvulsive Therapy (ECT) within eight weeks prior to enrolment; or treatment with an experimental drug within 30 days prior to enrolment.~3. Axis I diagnosis of substance abuse or dependence within the past month.~4. Significant risk of harm to self or others, in the opinion of the investigator.~5. Pregnancy or lactation in female subjects.~6. Liver function tests (AST and ALT) three times the upper limit of normal. -

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lurasidone (Type: EXPERIMENTAL): Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
- Treatment as usual (Type: NO_INTERVENTION): Patients randomized to this arm will continue their usual treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).